Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Non-Current Liabilities (2019 - 2021)

Keros Therapeutics' Total Non-Current Liabilities history spans 3 years, with the latest figure at $12.1 million for Q4 2021.

  • For Q4 2021, Total Non-Current Liabilities rose 57.66% year-over-year to $12.1 million; the TTM value through Dec 2021 reached $12.1 million, up 57.66%, while the annual FY2021 figure was $12.1 million, 57.66% up from the prior year.
  • Total Non-Current Liabilities reached $12.1 million in Q4 2021 per KROS's latest filing, up from $11.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $12.1 million in Q4 2021 to a low of $7.4 million in Q3 2020.
  • Average Total Non-Current Liabilities over 3 years is $9.4 million, with a median of $9.3 million recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: fell 25.93% in 2020, then soared 57.66% in 2021.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $10.3 million in 2019, then dropped by 25.93% to $7.7 million in 2020, then skyrocketed by 57.66% to $12.1 million in 2021.
  • Per Business Quant, the three most recent readings for KROS's Total Non-Current Liabilities are $12.1 million (Q4 2021), $11.5 million (Q3 2021), and $7.8 million (Q2 2021).